Pregabalin-Darnitsa kaps. 150 mg No. 14

medicament "Pregabalin-Darnitsa" is used at the following indications:

• neuropatichesky pain: treatment of neuropatichesky pain of peripheral or central origin at adults;
• epilepsy: additional therapy in partial convulsive attacks with secondary generalization or without that at adults;
• generalized anxiety disorder: treatment of a generalized anxiety disorder at adults;
• fibromyalgia.

Structure

1 capsule supports a pregabalin (active ingredient) of 75 mg or 150 mg.

Excipients: lactose monohydrate, starch corn, talc; solid gelatin capsules: gelatin, titan dioxide (E 171).

Contraindication

Hypersensitivity to active ingredient or to any excipient of medicine.

Route of administration and doses

Route of administration.

is Accepted irrespective of consumption of food.

only for oral administration.

Dose.

Range of medicament doses can change within 150-600 mg/days. To divide a daily dose into 2-3 receptions.

Neuropatichesky pain.

with the dose 150 mg/days divided into 2-3 receptions. Depending on the individual answer and tolerance of medicine the patient the dose can be increased up to 300 mg/days in 3-7 days, and if necessary – to the maximum dose of 600 mg/days in 7 days.

Epilepsy.

with the dose 150 mg/days divided into 2-3 receptions. Depending on the individual answer and tolerance of medicine the patient it is possible to increase a dose to 300 mg/days after the first week of treatment. In one week the dose can be increased to maximum – 600 mg/days.

Generalized anxiety disorder.

Dose which is divided into 2-3 receptions can change within 150-600 mg/days. Periodically it is necessary to reconsider need of continuation of therapy.

with a dose 150 mg/days. Depending on the individual answer and tolerance of medicine the patient it is possible to increase a dose to 300 mg/days after the first week of treatment. After one more week of reception it is possible to increase a dose to 450 mg/days. In one week the dose can be increased to maximum – 600 mg/days.

Fibromyalgia.

Recommended medicament dose for treatment of fibromyalgia makes from 300 to 450 mg/days. Treatment it is necessary to begin with use of a dose 75 mg twice a day (150 mg/days). Depending on efficiency and shipping it is possible to increase a dose to 150 mg twice a day (300 mg/days) within one week. For patients for whom use of a dose of 300 mg a day is insufficiently effective it is possible to increase a dose to 225 mg twice a day (450 mg/days). Though there is a research of use of a dose of 600 mg/days, proofs that use of this dose will have additional benefit, is not present; also such dose had the worst shipping. Considering dose-dependent side reactions, use of doses more than 450 mg/days it is not recommended. As pregabalin it is removed mainly by kidneys, it is necessary to adjust a medicament dose to patients with renal failures.

Cancellation of a pregabalin.

According to the operating clinical practice, it is recommended to stop therapy pregabaliny gradually, within not less than one week, irrespective of indications.

Feature of use

Pregnant

Woman capable to become pregnant / contraceptives for women and men.

, women, are capable to become pregnant, have to use effective remedies of contraception.

Pregnancy.

Appropriate data on use of a pregabalin by pregnant women are absent.

during the researches on animals showed reproductive toxicity. The potential risk for the person is unknown.

Medicine during pregnancy is applied only when the advantage for mother obviously exceeds possible risk for a fruit.

feeding Period breast.

in milk of the women nursing. Therefore feeding by a breast is not recommended at use of a pregabalin.

Fertility.

Clinical data on influence of a pregabalin on fertility of women are absent.

during clinical trial on studying influence of a pregabalin on mobility of spermatozoa the male healthy volunteers applied pregabalin in a dose 600 mg/days. After use of medicine within 3 months no influence on mobility of spermatozoa is revealed.

Safety and efficiency of Pregabalin-Darnitsa medicine at its use aged up to 18 years are not established to children by

. Safety and dosing of medicine at its use are unknown.

Drivers

Medicine can have insignificant or moderate impact on ability to run vehicles and to work with mechanisms. Can cause dizziness and drowsiness and thus to affect ability to run vehicles and to work with mechanisms. In this regard patients should recommend to abstain from control of vehicles, from work with a difficult technique or from other potentially dangerous activity, it will not become known yet whether this medicine affects their ability to such activity.

Most frequent side reactions at overdose pregabaliny drowsiness, confusion of consciousness, excitement and concern were p>

.

messages about spasms Also arrived.

to

it was Seldom reported about coma cases.

Treatment of overdose of a pregabalin consists in the general supporting actions and if necessary can include a hemodialysis (see the section "Route of Administration and Doses", the table).

Side reactions

Frequent registered side reactions were dizziness and drowsiness. Side reactions usually were easy or moderate degree. During the researches the rate of cancellation of medicine because of side reactions was 12% among the patients accepting pregabalin and 5% – among the patients receiving placebo. Dizziness and drowsiness were the most frequent side reactions which led to phase-out of medicine at researches in group of a pregabalin.

to Store

in original packing at a temperature not above 25 °C. To store out of children's reach.

Expiration date - 1.5 years.